Article
Spatial biomarker-driven deep learning model via digital pathology predicts response to PI3K inhibitor buparlisib in head and neck squamous cell carcinoma
2025-10-10
Abstract excerpt
<h4>ABSTRACT</h4> <h4>Purpose</h4> Buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel, demonstrated improved survival in the BERIL-1 trial for patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). However, predictive biomarkers of benefit remain undefined. We evaluated spatial biomarkers derived from hematoxylin and eosin (H&E) images using artificial intelligenc...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 7f8b1a92-94ef-57c9-aace-e516225bae58
- DOI
- 10.1101/2025.10.09.25337502
